Baseline characteristics in patients with interstitial lung diseases as predictors for progression: a real life study

1 W. D. Travis et al., “An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic inter-stitial pneumonias,” Am J Respir Crit Care Med, vol. 188, no. 6, pp. 733–748, Sep. 2013, doi: 10.1164/rccm.201308-1483ST. Search in Google Scholar

2 B. Kaul, V. Cottin, H. R. Collard, and C. Valenzuela, “Variability in Global Prevalence of Interstitial Lung Disease,” Frontiers in Medicine, vol. 8. Frontiers Media S.A., Nov. 04, 2021. doi: 10.3389/fmed.2021.751181. Search in Google Scholar

3 G. Raghu et al., “Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline,” Am J Respir Crit Care Med, vol. 205, no. 9, pp. E18–E47, May 2022, doi: 10.1164/rccm.202202-0399ST. Search in Google Scholar

4 M. Wijsenbeek and V. Cottin, “Spectrum of Fibrotic Lung Diseases,” New England Journal of Medicine, vol. 383, no. 10, pp. 958–968, Sep. 2020, doi: 10.1056/nejmra2005230. Search in Google Scholar

5 M. Kolb and M. Vašáková, “The natural history of progressive fibrosing interstitial lung diseases,” Respiratory Research, vol. 20, no. 1. BioMed Central Ltd., Mar. 14, 2019. doi: 10.1186/s12931-019-1022-1. Search in Google Scholar

6 L. Richeldi et al., “Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis,” New England Journal of Medicine, vol. 370, no. 22, pp. 2071–2082, May 2014, doi: 10.1056/nejmoa1402584. Search in Google Scholar

7 Monitorul Oficial al Romaniei – Anul 190 (XXXIV) – Nr 242 Bis, 2022, pp. 69–72. Search in Google Scholar

8 Yang IV, Fingerlin TE, Evans CM, Schwarz MI, Schwartz DA. MUC5B and Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2015 Nov;12 Suppl 2(Suppl 2):S193-9. doi: 10.1513/AnnalsATS.201503-110AW. PMID: 26595739; PMCID: PMC4722833. Search in Google Scholar

9 C. J. Ryerson et al., “Predicting survival across chronic interstitial lung disease: The ILD-GAP model,” Chest, vol. 145, no. 4, pp. 723–728, 2014, doi: 10.1378/chest.13-1474. Search in Google Scholar

10 A. W. Wong, C. J. Ryerson, and S. A. Guler, “Progression of fibrosing interstitial lung disease,” Respiratory Research, vol. 21, no. 1. BioMed Central Ltd., Jan. 29, 2020. doi: 10.1186/s12931-020-1296-3. Search in Google Scholar

11 S. L. F. Walsh et al., “Role of imaging in progressive-fibrosing interstitial lung diseases,” European Respiratory Review, vol. 27, no. 150. European Respiratory Society, 2018. doi: 10.1183/16000617.0073-2018. Search in Google Scholar

12 Irina Strambu, Ionela Belaconi, and Voicu Tudorache, “TOMOGRAFIA COMPUTERIZATÃ CU ÎNALTÃ REZOLUTIE (HRCT),” in GHID DE DIAGNOSTIC SI TRATAMENT AL PNEUMOPATIILOR INTERSTITIALE DIFUZE, 2015. Search in Google Scholar

13 J. H. Fisher et al., “Baseline characteristics and comorbidities in the CAnadian Registry for Pulmonary Fibrosis,” BMC Pulm Med, vol. 19, no. 1, Nov. 2019, doi: 10.1186/s12890-019-0986-4. Search in Google Scholar

14 Kawano-Dourado L, Doyle TJ, Bonfiglioli K, et al. Baseline characteristics and progression of a spectrum of interstitial lung abnormalities and disease in rheumatoid arthritis. Chest 2020, 158(4), pp. 1546–1554, doi.org/10.1016/j.chest.2020.04.061 Search in Google Scholar

15 Langford B, Diamantopoulos A, Maher TM et al. Using data on survival with idiopathic pulmonary fibrosis to estimate survival with other types of progressive fibrosis interstitial lung disease: a Bayesian framework. Adv Therap 2021. 39(151). DOI: 10.1007/s12325-021-02014-z. Search in Google Scholar

16 van de Sar I, Jones S, Clarke DL, Bonella F, Fourrier JM, Lewandowska K, Bermudo G, Simidchiev A, Strambu IR, Wijsenbeek MS, Parfrey H. Patient reported experiences and delays during the diagnostic pathway for pulmonary fibrosis: a multinational European survey. Front Med 2021. 8:711194. DOI: 10.3389/fmed.2021.711194 Search in Google Scholar